Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

Abstract: This disclosure relates to topical lithium agents including inhalable lithium agents for treating a viral infection characterized by a cytokine storm in the respiratory tract of a subject such as a human. Topical lithium formulations can be used to mitigate such viral infections, including coronavirus infections.

Abstract: The present disclosure provides methods and compositions for inhibiting Wnt5a expression in cells such as prostate cancer cells.

Abstract: Provided herein are formulations that can contain an effective amount of a PKC? inhibitor. Also provided herein are methods of inhibiting a PKC? in a subject in need thereof, that can include the step of administering an effective amount of a compound that is capable of inhibiting a PKC?.

Abstract: A surgical method of cataract fragmentation and extraction via microbubble cavitation is described. In particular, gas-filled microbubbles are injected into a lens capsule of a subject's eye, and cavitation of the microbubbles is activated by applied ultrasound energy. The ultrasound energy can be applied from an external device. The cavitation fragments cataract tissues without damaging other tissue, such as the lens capsule. Fragmented lens material is then aspirated from the lens capsule. The method can be used alone or in conjunction with other methods, such as phacoemulsification.

Abstract: The invention features probiotic bacteria expressing Clostridium difficile SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.

Abstract: Described herein is a method for eliminating or reducing ototoxicity in patients receiving a platinum based chemotherapeutic. In particular, are methods of reducing ototoxicity in a pediatric patient. The methods described herein include administering an effective amount of sodium thiosulfate to a patient in need thereof to reduce ototoxicity.

Abstract: Systems and methods for histotripsy and immunotherapy are provided. In some embodiments, histotripsy can be applied to a target tissue volume to lyse and solubilize the target tissue volume to release tumor antigens. In some embodiments, an immune response of the treatment can be evaluated. In other embodiments, an immune therapy can be applied after applying the histotripsy. In one embodiment, the lysed and solubilized cells can be extracted from the tissue. The extracted cells can be used to create immune therapies, including vaccines.

Abstract: The present invention features methods for characterizing mutational profiles in patients with bladder cancer.

Abstract: Embodiments discussed herein facilitate determination of whether lesions are benign or malignant. One example embodiment is a method, comprising: accessing medical imaging scan(s) that are each associated with distinct angle(s) and each comprise a segmented region of interest (ROI) of that medical imaging scan comprising a lesion associated with a first region and a second region; providing the first region(s) of the medical imaging scan(s) to trained first deep learning (DL) model(s) of an ensemble and the second region(s) of the medical imaging scan(s) to trained second DL model(s) of the ensemble; and receiving, from the ensemble of DL models, an indication of whether the lesion is a benign architectural distortion (AD) or a malignant AD.

Abstract: An external catheter system can comprise an external catheter comprising an engagement portion that is configured to receive and sealingly engage at least a portion of a penis of a user and an outlet. The system can further comprise a negative pressure source. A conduit can couple the negative pressure source to the external catheter. At least one of the external catheter and the conduit can comprise a portion that, upon application of a negative pressure by the negative pressure source, is configured to collapse to provide a pressure drop between the negative pressure source and the engagement portion of the external catheter.

Abstract: A medication adherence system and corresponding medication box for improving medication adherence. The system includes the medication box, which is transparent and has a machine-readable marker, such as a QR code, on or beneath the floor thereof. The marker is capable of being scanned and read through the transparent bottoms of individual chambers. Data embedded in the marker includes, but is not limited to, the user's medication plan, the date and time when the medication is to be ingested, and instructions for recording the date and time when the marker is scanned and read. The underlying software program/application processes this information and provides an indication as to the user's compliance with the medication plan.

Abstract: The present invention describes compositions and method for improving outcomes after injury to the central nervous system wherein complement signaling is activated. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a therapeutic agent comprising a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement, and wherein therapeutic agent is administered in combination with rehabilitation therapy or thrombolytic agent.

Abstract: Provided are methods for delaying or preventing onset of progressive memory decline by administering a muscarinic M2 receptor blocking compound to patients identified as at risk of developing a condition characterized by progressive memory decline, prior to onset of the condition.

Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.

Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.

Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistence to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

Abstract: Disclosed herein, are decoy peptides or polypeptides capable of neutralizing and/or inhibiting the binding of anti-Ro antibodies to a hERG potassium channel extracellular pore region, and pharmaceutical compositions containing the decoy peptides or polypeptides and methods of use.

Abstract: A method of performing cardiopulmonary resuscitation on a mammalian subject including the step of delivering an effective amount of a gliflozin solution during cardiac resuscitation through an intravenous or intraosseous route.